What is the recommended dose, administration schedule, contraindications, and monitoring for sibeprenlimab in adults with primary IgA nephropathy and proteinuria who are already receiving maximally tolerated angiotensin‑converting enzyme inhibitor or angiotensin‑receptor blocker therapy (with or without a sodium‑glucose cotransporter‑2 inhibitor)?

Sibeprenlimab for IgA Nephropathy

Sibeprenlimab should be administered subcutaneously at 400 mg every 4 weeks for patients with IgA nephropathy and persistent proteinuria despite maximally tolerated ACE inhibitor or ARB therapy (with or without SGLT2 inhibitor). 1, 2

Recommended Dosing and Administration

Dose: 400 mg subcutaneous injection 1, 2

Schedule: Once every 4 weeks (every 28 days) 1, 2

Duration: Treatment was administered for 100 weeks (26 doses) in the pivotal VISIONARY trial 2

Route: Subcutaneous administration only 2

• The phase 3 VISIONARY trial established this subcutaneous regimen after phase 2 studies used intravenous dosing at 2-8 mg/kg monthly 3
• Subcutaneous administration offers practical advantages over intravenous delivery for long-term management 4

Patient Selection Criteria

Eligible patients include adults with:

• Biopsy-confirmed primary IgA nephropathy 1, 2
• Proteinuria ≥0.5 g/day (mean baseline 24-hour urine protein-to-creatinine ratio 1.54 g/g in VISIONARY) 2
• Already receiving maximally tolerated renin-angiotensin system inhibitor therapy (97.8% of trial participants) 2
• With or without SGLT2 inhibitor (45.1% of trial participants were on SGLT2i) 2
• Mean baseline eGFR of 64.2 ml/min per 1.73 m² in the pivotal trial 2

Contraindications

No specific contraindications are established in the available evidence. 1, 3, 5

• Phase 1 studies in healthy volunteers showed no serious adverse events 5
• The phase 3 trial reported no deaths during the treatment period 1
• Serious adverse events occurred in only 3.5% of sibeprenlimab-treated patients versus 4.4% with placebo 1

Important considerations:

• Sibeprenlimab reversibly suppresses immunoglobulins (IgA, IgG, IgM) in a dose-dependent manner 5
• However, antigen-specific vaccination responses were preserved after tetanus/diphtheria recall vaccination 5
• No increased infection risk was observed despite immunoglobulin suppression 4, 5

Monitoring Requirements

Baseline Assessment

Before initiating sibeprenlimab:

• Confirm biopsy-proven IgA nephropathy with IgA-dominant mesangial deposits 6
• Exclude secondary causes: IgA vasculitis, infection-related glomerulonephritis, cirrhosis, inflammatory bowel disease, celiac disease, viral hepatitis, autoimmune diseases 6
• Document 24-hour urine protein-to-creatinine ratio 1, 2
• Measure baseline eGFR and serum creatinine 2
• Optimize ACE inhibitor or ARB to maximally tolerated dose per KDIGO guidelines 7
• Target blood pressure <120/70 mm Hg using standardized office measurement 7

During Treatment Monitoring

Proteinuria assessment:

• Monitor 24-hour urine protein-to-creatinine ratio at 9 months as primary efficacy endpoint 1
• In the VISIONARY trial, sibeprenlimab reduced proteinuria by 50.2% versus a 2.1% increase with placebo (51.2% relative reduction, P<0.001) 1

Renal function:

• Monitor serum creatinine and eGFR regularly 7
• Continue ACE inhibitor/ARB unless creatinine rises >30% or refractory hyperkalemia develops 7
• Be aware that SGLT2 inhibitors may cause osmotic nephropathy in rare cases, particularly after dose escalation in patients with pre-existing CKD 8

Laboratory monitoring:

• Serum APRIL levels decrease by 95.8% at week 48 1
• Pathogenic galactose-deficient IgA1 reduces by 67.1% from baseline 1
• Monitor for electrolyte abnormalities, particularly potassium if on concurrent RAS blockade 7
• Treat metabolic acidosis if serum bicarbonate <22 mmol/L 7

Safety monitoring:

• Assess for adverse events at each visit 1
• The safety profile appears similar to placebo with no specific pattern of adverse events 1, 3
• No routine immunoglobulin level monitoring is required based on trial protocols, though levels will decrease 5

Supportive Care Continuation

Maintain concurrent therapies per KDIGO guidelines:

• Continue maximally tolerated ACE inhibitor or ARB 7
• Maintain SGLT2 inhibitor if already prescribed 2
• Restrict dietary sodium to <2.0 g/day 7
• Target blood pressure <120/70 mm Hg 7
• Counsel patients to hold ACE inhibitor/ARB during volume depletion or sick days 7
• Use potassium-wasting diuretics or potassium binders if needed to maintain normal potassium and allow continued RAS blockade 7

Clinical Efficacy Context

Sibeprenlimab represents a disease-modifying approach targeting the underlying pathogenesis of IgA nephropathy by neutralizing APRIL, a key cytokine driver. 1, 4

• The mechanism differs from supportive therapies (ACE inhibitors, ARBs, SGLT2 inhibitors) that manage downstream consequences 4
• Phase 2 data showed 47-62% reduction in proteinuria across dose ranges versus 20% with placebo 3
• eGFR was stabilized or improved with sibeprenlimab versus decline with placebo in phase 2 3
• The key secondary endpoint of annualized eGFR slope over 24 months will be reported at trial completion 1

Important Caveats

• Long-term safety data beyond the current trial duration are not yet available 4
• Whether sibeprenlimab improves hard clinical outcomes (kidney failure, mortality) requires longer follow-up 4
• The drug is administered in addition to, not as replacement for, optimized supportive care with RAS inhibition and blood pressure control 7, 2
• Patients should maintain lifestyle modifications including sodium restriction, weight normalization, smoking cessation, and regular exercise 7